MedPath

Fluorescein

Generic Name
Fluorescein
Brand Names
Ak-fluor, Altafluor, Diofluor, Fluorescite, Fluress
Drug Type
Small Molecule
Chemical Formula
C20H12O5
CAS Number
2321-07-5
Unique Ingredient Identifier
TPY09G7XIR

Overview

A phthalic indicator dye that appears yellow-green in normal tear film and bright green in a more alkaline medium, such as the aqueous humor, and is used therapeutically as a diagnostic aid in corneal injuries and corneal trauma. It has been approved by FDA for use in externally applied drugs and cosmetics. (From Merck Index, 12th ed; American Medical Association Drug Evaluations; 1995, p2275)

Indication

For diagnostic imaging. Primarily indicated in diagnostic fluorescein angiography or angioscopy of the fundus and of the iris vasculature.

Associated Conditions

  • Peritoneal dialysis therapy
  • Pneumocystis Jirovecii Pneumonia

Research Report

Published: Aug 19, 2025

Fluorescein: A Comprehensive Monograph on its Chemistry, Pharmacology, and Evolving Clinical Utility

1.0 Executive Summary

Fluorescein is a synthetic organic xanthene dye that functions as a highly conspicuous fluorophore, a property that has established it as an indispensable diagnostic agent in medicine for over a century. Identified by DrugBank ID DB00693 and CAS Number 2321-07-5, this small molecule is most renowned for its central role in ophthalmology. Administered intravenously as its water-soluble sodium salt, it is the cornerstone of fluorescein angiography, a procedure critical for visualizing the retinal and choroidal vasculature to diagnose and manage a wide spectrum of disorders, including diabetic retinopathy and age-related macular degeneration. In its water-insoluble free acid form, it is applied topically via ophthalmic strips to detect defects in the corneal epithelium, such as abrasions and ulcers. The fundamental mechanism of action is physical rather than pharmacological; it absorbs blue light and emits a brilliant yellowish-green fluorescence, acting as a passive tracer within biological systems. Its pharmacokinetic profile is characterized by rapid distribution, extensive and swift hepatic metabolism to a fluorescent monoglucuronide metabolite, and primary elimination through renal excretion. While generally considered safe, Fluorescein carries a well-defined risk of adverse reactions, ranging from common, mild effects like nausea to rare but life-threatening hypersensitivity events that necessitate universal precautions during intravenous administration. Beyond its traditional ophthalmic applications, Fluorescein is experiencing a renaissance, with its utility expanding into fluorescence-guided surgery for tumor resection, oncology, and forensic science, demonstrating how technological advancements can unlock new potential in a long-established compound.

2.0 Identification and Physicochemical Properties

Continue reading the full research report

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Bausch & Lomb Incorporated
24208-734
OPHTHALMIC
2.6 mg in 1 mL
8/31/2022
A-S Medication Solutions
50090-4535
INTRAVENOUS
100 mg in 1 mL
8/15/2016
Altaire Pharmaceuticals Inc.
59390-205
OPHTHALMIC
2.5 mg in 1 mL
11/1/2022
Akorn
17478-403
OPHTHALMIC
0.6 mg in 1 1
3/22/2012
Oceanside Pharmaceuticals
68682-732
OPHTHALMIC
2.6 mg in 1 mL
3/19/2020
Akorn
17478-253
INTRAVENOUS
100 mg in 1 mL
8/15/2016
Akorn
17478-404
OPHTHALMIC
1 mg in 1 1
3/22/2012
Nexus Pharmaceuticals LLC
14789-123
INTRAVENOUS
250 mg in 1 mL
10/25/2023
Bausch & Lomb Americas Inc.
82260-734
OPHTHALMIC
2.6 mg in 1 mL
3/16/2023
HF Acquisition Co LLC, DBA HealthFirst
51662-1533
INTRAVENOUS
100 mg in 1 mL
8/8/2021

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
FLUORETS (FLUORESCEIN OPHTHALMIC STRIPS)
dioptic pharmaceuticals inc
02026252
Strip - Ophthalmic
1 MG
12/31/1994
FLUORESCEIN
pharma stulln inc.
02027097
Solution - Intravenous
250 MG / ML
12/31/1994
ODAN-FLUORESCEIN
odan laboratories ltd
00622869
Solution - Intravenous
100 MG / ML
12/31/1984
ODAN-FLUORESCEIN
odan laboratories ltd
00622877
Liquid - Intravenous
250 MG / ML
12/31/1985
MINIMS FLUORESCEIN SODIUM
bausch & lomb inc
02148390
Drops - Ophthalmic
2 % / W/V
12/31/1995
BIO GLO
white ophthalmic services & supply co ltd
02317281
Strip - Ophthalmic
1 MG
1/28/2009
FLUORESCEIN
pharma stulln inc.
02027089
Solution - Intravenous
100 MG / ML
12/31/1994
ODAN-FLUORETS
odan laboratories ltd
00687812
Strip - Ophthalmic
1 MG
12/31/1986
FLUORETS - STP OPH 1MG
chauvin pharmaceuticals limited
02179539
Strip - Ophthalmic
1 MG
11/1/1996
FLUOROX
white ophthalmic services & supply co ltd
02354993
Solution - Ophthalmic
0.25 %
11/28/2011

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.